key: cord-0796806-htzkzow4
authors: Cacabelos, Ramón; Cacabelos, Pablo; Torrellas, Clara
title: Personalized Medicine of Alzheimer’s Disease
date: 2014-05-02
journal: Handbook of Pharmacogenomics and Stratified Medicine
DOI: 10.1016/b978-0-12-386882-4.00027-x
sha: cd0ea73ea20e5bbc9bad3ecaef118dddcf6a0ce5
doc_id: 796806
cord_uid: htzkzow4

Alzheimer’s disease (AD) is a major problem of health and disability, with a relevant economic impact on society (e.g., €177 billion in Europe). Despite important advances in pathogenesis, diagnosis, and treatment, The primary causes of AD remain elusive, accurate biomarkers are not well characterized, and available pharmacological treatments are not cost-effective. As a complex disorder, AD is polygenic and multifactorial: hundreds of defective genes distributed across the human genome may contribute to its pathogenesis (with the participation of diverse environmental factors, cerebrovascular dysfunction, and epigenetic phenomena) and lead to amyloid deposition, neurofibrillary tangle formation, and premature neuronal death. Future perspectives for the global management of AD predict that structural and functional genomics and proteomics may help in the search for reliable biomarkers, and that pharmacogenomics may be an option in optimizing drug development and therapeutics.

and developing countries, bringing about future challenges in terms of health policy and disability rates.

In the United States, rates for the leading causes of death are heart disease (200.2 per 100,000), cancer (180.7 per 100,000), and stroke (43.6 per 100,000). AD is the fifth leading cause of death in people older than 65 years of age, representing 71,600 deaths per year. AD affects approximately 5.4 million individuals in the United States and is estimated to affect up to 16 million by 2050 [2] . Disability caused by senility and dementia affects 9.2 per 1000 in the population aged 65-74 years, 33 Chapter Outline [3, 4] . In low-to middle-income countries, dementia makes the largest contribution to disability, with a median population-attributable prevalence fraction of 25.1%, followed by stroke (11.4%), limb impairment (10.5%), arthritis (9.9%), depression (8.3%), eyesight problems (6.8%), and gastrointestinal impairments (6.5%) [5] .

In Western countries, AD is the most prevalent form of dementia (45-60%), followed by vascular dementia (30-40%) , and mixed dementia (10-20%), which in people older than 85 years of age may account for more than 80% of cases.

The different forms of dementia pose several challenges to society and to the scientific community: (1) they represent an epidemiological problem and a socioeconomic, psychological, and family burden; (2) most of them have an obscure/complex pathogenesis; (3) their diagnosis is not easy and lacks specific biomarkers; and (4) their treatment is difficult and inefficient.

In terms of economic burden, approximately 10-20% of direct costs are associated with pharmacological treatment, with a gradual increase that parallels the severity of the disease. A Canadian study [6] shows that the mean total cost to treat patients with very mild AD is $367 per month, compared with $4063 per month for patients with severe or very severe AD. Only 20-30% of patients with dementia respond appropriately to conventional drugs, and the onset of adverse drug reactions imposes the need for other drugs to neutralize side effects, thus multiplying the initial cost of the pharmacological treatment and the health risk for the patients [7] . Wimo et al. [8] studied the economic impact of dementia in Europe in the EU-funded Eurocode project and found that the total cost of dementia in EU27 countries in 2008 was estimated to be €160 billion (€22,000 per dementia patient per year), of which 56% were costs of informal care. The corresponding costs for the whole of Europe were €177 billion. Informal caregiver costs were the largest cost component, accounting for about half to just over 60% of total societal costs, depending on the country and AD severity [9] .

In addition (and related) to the problem of direct and indirect costs for the management of dementia, there is an alarming abuse of inappropriate psychotropic drug consumption worldwide. Antipsychotic medications are taken by more than 30% of elderly patients with dementia [10] , and conventional antipsychotics are associated with a higher risk of all-cause mortality among nursing home residents [11] .

Abuse, misuse, self-prescription, and uncontrolled medical prescription of CNS drugs are becoming major problems with unpredictable consequences for brain health. The pharmacological management of dementia is an issue of special concern because of the polymedication required to modulate its symptomatic complexity where cognitive decline, behavioral changes, and psychomotor deterioration coexist. In parallel, a growing body of fresh knowledge is emerging on the pathogenesis of dementia, together with data on the neurogenomics and pharmacogenomics of CNS disorders. The incorporation of this new armamentarium of molecular pathology and genomic medicine into daily medical practice, together with educational programs for the correct use of drugs, must help researchers and clinicians to (1) understand AD pathogenesis; (2) establish an early diagnosis; and (3) optimize therapeutics either as a preventive strategy or as formal symptomatic treatment [7, 12] .

Common features of neurodegenerative disorders include the following: For instance, the neuropathological hallmarks of AD (amyloid deposition in senile plaques, neurofibrillary tangle formation, and neuronal loss) are merely the phenotypic expression of a pathogenic process in which different gene clusters and their products are potentially involved [7, 12] .

A large number of the genes that form the structural architecture of the human genome are expressed in the brain in a time-dependent manner along the lifespan. The cellular complexity of the CNS (10 3 different cell types) and synapses (each of the 10 11 neurons in the brain having around 10 3 -10 4 synapses with a complex multiprotein structure integrated by 10 3 different proteins) requires very powerful technology for gene expression profiling, which is still in its very early stages and is not devoid of technical obstacles and limitations [13] . Transcripts of 16,896 genes have been measured in different CNS regions. Each region possesses its own unique transcriptome fingerprint that is independent of age, gender, and energy intake. Fewer than 10% of genes are affected by age, diet, or gender, with most of these changes occurring between middle and old age. Gender and energy restriction have robust influences on the hippocampal transcriptome of middle-aged animals. Prominent functional groups of age-and energy-sensitive genes are those encoding proteins involved in DNA damage responses, mitochondrial and proteasome functions, cell fate determination, and synaptic vesicle trafficking [14] .

The introduction of novel procedures in an integral genomic medicine protocol for CNS disorders and dementia is imperative in drug development and in clinical practice in order to improve diagnostic accuracy and to optimize therapeutics. Personalized strategies, adapted to the complexity of each case, are essential to depict a clinical profile based on specific biomarkers correlating with individual genomic profiles [7, 15] .

Our understanding of the pathophysiology of CNS disorders and dementia has advanced dramatically during the last 30 years, especially in terms of their molecular pathogenesis and genetics. The drug treatment of CNS disorders has also made remarkable strides with the introduction of many new drugs for the treatment of schizophrenia, depression, anxiety, epilepsy, Parkinson's disease, and AD, among many other quantitatively and qualitatively important neuropsychiatric disorders. Improvement in terms of clinical outcome, however, has fallen short of expectations, with up to one-third of patients continuing to experience clinical relapse or unacceptable medication-related side effects in spite of efforts to identify optimal treatment regimes with one or more drugs. Potential reasons for this historical setback might be: (1) that the molecular pathology of most CNS disorders is still poorly understood; (2) that drug targets are inappropriate, not fitting into the real etiology of the disease; (3) that most treatments are symptomatic but not antipathogenic; (4) that the genetic component of most CNS disorders is poorly defined; and (5) that the understanding of genome-drug interactions is very limited [7, 12] .

The optimization of CNS therapeutics requires the establishment of new postulates regarding (1) the costs of medicines, (2) the assessment of protocols for multifactorial treatment in chronic disorders, (3) the implementation of novel therapeutics addressing causative factors, and (4) the establishment of pharmacogenomic strategies for drug development [12] . Personalized therapeutics based on individual genomic profiles implies the characterization of five types of gene clusters: l Genes associated with disease pathogenesis l Genes associated with the mechanism of action of drugs l Genes associated with drug metabolism (phase I and II reactions) l Genes associated with drug transporters l Pleiotropic genes involved in multifaceted cascades and metabolic reactions

More than 3000 genes distributed across the human genome have been screened for association with AD during the past 30 years [16] . In the Alzgene database [17] there are 695 genes potentially associated with AD, of which the top ten are (in decreasing order of importance): APOE (19q13.2), BIN1 (2q14), CLU (8p21-p12), ABCA7 (19p13.3), CR1 (1q32), PICALM (11q14), MS4A6A (11q12.1), CD33 (19q13.3), MS4A4E (11q12.2), and CD2AP (6p12). Potentially defective genes associated with AD represent about 1.39% (35,252.69 Kb) of the human genome, which is integrated by 36 (1.15%; 1968.22 Kb) , with the highest proportion (related to the total number of genes mapped on a single chromosome) located on chromosome 10 and the lowest on chromosome Y [18] (Figure 27 .1).

The genetic and epigenetic defects identified in AD can be classified into four major categories: Mendelian mutations; susceptibility SNP; mtDNA mutations; and epigenetic changes. Mendelian mutations affect genes directly linked to AD, including 32 mutations in the amyloid beta precursor protein (APP) gene (21q21)(AD1), 165 mutations in the presenilin 1 (PSEN1) gene (14q24.3)(AD3), and 12 mutations in the presenilin 2 (PSEN2) gene (1q31-q42) (AD4) [16] [17] [18] [19] [20] . PSEN1 and PSEN2 are important determinants of γ-secretase activity responsible for proteolytic cleavage of APP and NOTCH receptor proteins. Mendelian mutations are very rare in AD (1:1000). Mutations in exons 16 and 17 of the APP gene appear with a frequency of 0.30% and 0.78%, respectively, in AD patients. Likewise, PSEN1, PSEN2, and microtubule-associated protein Tau (MAPT)(17q21.1) mutations are present in less than 2% of cases. Mutations in these genes confer specific phenotypic profiles to patients with dementia: amyloidogeneic pathology associated with APP, PSEN1, and PSEN2 mutations and tauopathy associated with MAPT mutations represent the two major pathogenic hypotheses for AD [16] [17] [18] [19] [20] [21] .

Multiple polymorphic risk variants can increase neuronal vulnerability to premature death (see Appendix A). Among these susceptibility genes, the apolipoprotein E (APOE) gene (19q13.2)(AD2) is the most prevalent as a risk factor for AD, especially in those subjects harboring the APOE-4 allele ( Figure 27 .2), whereas carriers of the APOE-2 allele might be protected against dementia. APOE-related pathogenic mechanisms are also associated with brain aging and with the neuropathological hallmarks of AD [16] .

The dual amyloidogenic-tauopathic theory of AD has dominated the pathogenic universe of AD-related neurodegeneration (and divided the research community) for the past 50 years, nourished by the presence of APP, PSEN1, PSEN2, and MAPT mutations in a very small number of cases with early-onset AD. Nevertheless, this theory does not explain AD pathogenesis in full, and consequently novel (or complementary) theories have been emerging recently and during the past decades. A summary of the pathogenic events in AD is given in the following sections.

As a complex polygenic/multifactorial disorder, in which hundreds of polymorphic variants of risk might be involved (Appendix A, Figure 27 .1), AD fulfils the "golden rule" of complex disorders, according to which the larger the number of genetic defects distributed in the human genome, the earlier the onset of the disease and the poorer its therapeutic response to conventional treatments; conversely, the smaller the number of pathogenic SNPs, the later the onset of the disease and the better its therapeutic response to different pharmacological interventions [12, 16, [22] [23] [24] [25] [26] [27] [28] . Genetic variation associated with different diseases interferes with microRNA-mediated regulation by creating, destroying, or modifying microRNA (miRNA) binding sites. miRNAtarget variability is a ubiquitous phenomenon in the adult human brain which may influence gene expression in physiological and pathological conditions. AD-related SNPs interfere with miRNA gene regulation and affect AD susceptibility. Significant interactions include target SNPs present in seven genes related to AD prognosis with the miRNAs miR-214, -23a and -23b, -486-3p, -30e*, -143, -128, -27a and -27b, -324-5p, and -422a. The dysregulated miRNA network contributes to aberrant gene expression in AD [29] [30] [31] .

Epigenetic factors have emerged as important mediators of development and aging, gene-gene and gene-environmental interactions, and the pathophysiology of complex disorders. Major epigenetic mechanisms (DNA methylation, histone modifications and chromatin remodeling, and noncoding RNA regulation) may contribute to AD pathology [30, 31] .

Vascular and metabolic dysfunctions are key components in AD pathology throughout the course of disease. Although common denominators between vascular and metabolic dysfunction are oxidative stress and Aβ [32] , genetic factors and cardiovascular risk factors may also account for the cerebrovascular damage present in AD [33] . Inherited polymorphisms of the vascular susceptibility gene Ninjurin2 (NINJ2) are associated with AD risk [34] . Endothelial dysfunction has been implicated as a crucial event in the development of AD.

Breakdown of the blood-brain barrier (BBB) as a result of disruption of tight junctions and transporters leads to increased leukocyte transmigration and is an early event in the pathology of many CNS disorders. BBB breakdown leads to neuroinflammation and oxidative stress, with mitochondrial dysfunction. The high concentration of mitochondria in cerebrovascular endothelial cells might account for the sensitivity of the BBB to oxidant stressors [35, 36] . Chronic brain hypoperfusion may be sufficient to induce premature neuronal death and dementia in vulnerable subjects [16, [23] [24] [25] [37] [38] [39] . APOE-related changes in cortical oxygenation and hemoglobin consumption are evident, as revealed by brain optical topography analysis, and reflect that APOE-4 carriers exhibit deficient brain hemodynamics and a poorer panneocortical oxygenation than do APOE-3 or APOE-2 carriers [18] . Hypoperfusion in frontal, parietal, and temporal regions is a common finding in AD. White matter hyperintensities (WMH) correlate with age and with disease severity [40] .

Cerebral amyloid angiopathy (CAA) accounts for the majority of primary lobal intracerebral hemorrhages (ICH) among the elderly, and represents the cause of 20% of spontaneous ICHs in patients over 70 years of age. The basis for this disease process is the deposition and formation of eventually destructive amyloid plaques in the walls of brain vessels, predominantly arterial but not excluding venules and capillaries. CAA and CAA-associated microhemorrhages may also participate in the pathogenesis of AD [41] . Aβ deposition in asymptomatic elderly individuals is associated with lobar MH (LMH).

LMH is present in 30.8% of AD, 35.7% of MCI, and 19.1% of controls [42] . Neurovascular dysfunction in AD leads to reduced clearance across the BBB and accumulation of neurotoxic Aβ peptides in the brain. The ABC transport protein P-glycoprotein (P-gp, ABCB1) is involved in the export of Aβ from the brain into the blood. P-gp, LRP1, and RAGE mRNA expression is reduced in mice treated with Aβ 1-42 . In addition to the age-related decrease in P-gp expression, Aβ 1-42 itself downregulates the expression of P-gp and other Aβ transporters, which could exacerbate the intracerebral accumulation of Aβ and thereby accelerate neurodegeneration in AD and cerebral β-amyloid angiopathy [43] .

β-Amyloid deposits in senile and neuritic plaques and hyperphosphorylated tau proteins in neurofibrillary tangles (NFT) are extracellular and intracellular expressions, respectively, of the AD neuropathological phenotype, together with selective neuronal loss in hippocampal and neocortical regions. Aβ plaque in the brain is the primary (postmortem) diagnostic criterion of AD. The main component of senile plaques is Aβ, a 39-43 amino acid peptide, generated by the proteolytic cleavage of amyloid precursor protein (APP) by the action of beta-and gamma-secretases. Aβ is neurotoxic, and this neurotoxicity is related to its aggregation state [16] [17] [18] [19] [20] [21] .

Neuronal loss is a pathognomonic finding in AD and the final common path of multiple pathogenic mechanisms leading to neurodegeneration in dementia. Atrophy of the medial temporal lobe, especially the hippocampus and the parahippocampal gyrus, is considered to be AD's most predictive structural brain biomarker. The medial and posterior parts of the parietal lobe seem to be preferentially affected, compared to the other parietal lobe parts [18] .

An imbalance of different neurotransmitters (glutamate, acetylcholine, noradrenaline, dopamine, serotonin, and some neuropeptides) has been proposed as the neurobiological basis of behavioral symptoms in AD. Altered reuptake of neurotransmitters by vesicular glutamate transporters (VGLUTs), excitatory amino acid transporters (EAATs), the vesicular acetylcholine transporter (VAChT), the serotonin reuptake transporter (SERT), or the dopamine reuptake transporter (DAT) are involved in the neurotransmission imbalance in AD. Protein and mRNA levels of VGLUTs, EAAT1-3, VAChT, and SERT are reduced in the disease [44] .

Oxidative damage is a classic pathogenic mechanism of neurodegeneration [36, 45] . It is greater in brain tissue from patients with AD than age-matched controls. Tayler et al. [46] studied the timing of this damage in relation to other pathogenic AD processes. Antioxidant capacity is elevated in AD and directly related to disease severity as indicated by the Braak tangle stage and the amount of insoluble Aβ. Accumulation of Aβ has been shown in brain mitochondria of AD patients and in AD transgenic mouse models. The presence of Aβ in mitochondria leads to free radical generation and neuronal stress.

A novel mitochondrial Aβ-degrading enzyme, presequence protease (Pre), has been identified in the mitochondrial matrix. hPreP activity is decreased in AD human brains and in the mitochondrial matrix of AD transgenic mouse brains (TgmAβPP and TgmAβPP/ABAD). Mitochondrial fractions isolated from AD brains and TgmAβPP mice have higher levels of 4-hydroxynonenal, an oxidative product. Cytochrome c oxidase activity is significantly reduced in the AD mitochondria. Decreased PreP proteolytic activity, possibly due to enhanced ROS production, may contribute to Aβ accumulation in mitochondria, leading to mitochondrial toxicity and neuronal death in AD [47] .

Cholesterol seems to be intimately linked with the generation of amyloid plaques, which are central to AD pathogenesis. APOE variants are determinants in cholesterol metabolism and diverse forms of dyslipoproteinemia [12, 48] . Cholesterol protects the Aβ-induced neuronal membrane disruption and inhibits beta-sheet formation of Aβ on the lipid bilayer [49] . Jones et al. [50] found a significant over-representation of association signals in pathways related to cholesterol metabolism and the immune response in both of the two largest genome-wide association studies for LOAD.

Several genes associated with immune regulation and inflammation show polymorphic variants of risk in AD, and abnormal levels of diverse cytokins have been reported in the brain, CSF, and plasma of AD patients [16, 23] . The activation of inflammatory cascades has been consistently demonstrated in AD pathophysiology, in which reactive microglia are associated with Aβ deposits and clearance. Resident microglia fail to trigger an effective phagocytic response to clear Aβ deposits, although they mainly exist in an "activated" state. Oligomeric Aβ (oAβ) can induce more potent neurotoxicity when compared with fibrillar Aβ (fAβ). Aβ fibrils, not Aβ oligomers, increase microglial phagocytosis [51] . Among several putative neuroinflammatory mechanisms, the TNF-α signaling system has a central role in this process. In AD, TNF-α levels are altered in serum and CSF. The abnormal production of inflammatory factors may accompany the progression from mild cognitive impairment (MCI) to dementia. Abnormal activation of the TNF-α signaling system, represented by increased expression of sTNFR1, is associated with a higher risk of progression from MCI to AD [52] .

Old and new theories suggest that different toxic agents, from metals (e.g., aluminium, copper, zinc, iron) to biotoxins and pesticides, might contribute to neurodegeneration. Dysfunctional homeostasis of transition metals is believed to play a role in AD pathogenesis [18] .

Many novel pathogenic mechanisms potentially involved in AD neurodegeneration have been proposed in recent times. Moreover, there has been a revival of some old hypotheses. Examples of pathogenic players in AD, other than those just discussed, include the Ca 2+ hypothesis, insulin resistance, NGF imbalance, glycogen synthase kinase-3 (GSK-3), advanced glycation end products (AGEs) and their receptors (RAGE), the efflux transporter P-glycoprotein (P-gp), c-Abl tyrosine kinase, post-transcriptional protein alterations that compromise the proteasome system and the chaperone machinery (HSPB8-BAG3), autophagy as a novel Aβ-generating pathway, hypocretin (orexin), cathepsin B, Nogo receptor proteins, adipocytokines and CD34 + progenitor cells, CD147, impairment of synaptic plasticity (PSD-95), anomalies in neuronal cell division and apoptosis, stem cell factor (SCF), telomere shortening, deficiency in repair of nuclear and mitochondrial DNA damage, and microDNAs [18] .

AD's phenotypic features represent the biomarkers to be used as diagnostic predictors and the expression of pathogenic events to be modified with an effective therapeutic intervention. Important differences have been found in the AD population (as compared with healthy subjects) in different biological parameters, including blood pressure, glucose, cholesterol and triglyceride levels, transaminase activity, hematological parameters, metabolic factors, thyroid function, brain hemodynamic parameters, and brain mapping activity [7, [23] [24] [25] [53] [54] [55] [56] [57] [58] [59] .

These clinical differences are clear signs of comorbidity rather than typical features of AD. Blood pressure values, glucose levels, and cholesterol levels are higher in AD than in healthy elderly subjects. Approximately 20% of AD patients are hypertensive, 25% are diabetics, 50% are hypercholesterolemic, and 23% are hypertriglyceridemic. More than 25% of patients exhibit high GGT activity, 5-10% show anemic conditions, 30-50% show an abnormal cerebrovascular function characterized by poor brain perfusion, and more than 60% have an abnormal electroencephalographic pattern, especially in frontal, temporal, and parietal regions, as revealed by quantitative EEG (qEEG) or computerized mapping [7, 12, 23, 54] . Significant differences are currently seen between females and males, indicating the effect of gender on the phenotypic expression of the disease. In fact, the prevalence of dementia is 10-15% higher in females than in males from 65-85 years of age. All of these parameters are highly relevant when treating AD patients, because some of them reflect a concomitant pathology that also needs therapeutic consideration.

AD biomarkers can be differentiated into several categories: (1) neuropathological markers; (2) structural and functional neuroimaging markers; (3) neurophysiological markers (EEG, qEEG, brain mapping); (4) biochemical markers in body fluids (e.g., blood, urine, saliva, CSF); and (5) genomic markers (structural and functional genomics, proteomics, metabolomics).

Plaques and tangles in the hippocampus and cortex are still considered the seminal findings in AD neuropathology and are the conventional means of establishing the boundary between amyloidopathies and tauopathies; however, both phenotypic markers are also present in normal brains, in more than 60% of cases with traumatic brain injury, and in many other brain disorders [60] .

Structural and functional neuroimaging techniques (MRI, fMRI, PET, SPECT) are essential tools in the diagnosis of dementia, although the specificity of visual observations in degenerative forms of dementia is of doubtful value. Nevertheless, these procedures are irreplaceable for a differential diagnosis. There is a characteristic regional impairment in AD that involves mainly the temporo-parietal association cortices, the mesial temporal structures, and, to a more variable degree, the frontal association cortex. This pattern of functional impairment can provide a biomarker for diagnosis of AD and other neurodegenerative dementias at the clinical stage of mild cognitive impairment, and for monitoring its progression. Healthy young APOE ε4 carriers have smaller hippocampal volumes than APOE ε2 carriers.

The difference in hippocampal morphology is cognitively/clinically silent in young adulthood, but can render APOE ε4 carriers more prone to the later development of AD, possibly because of lower reserve cognitive capacity [61] . LOAD patients exhibit a selective parahippocampal white matter (WM) loss, while EOAD patients experience a more widespread pattern of posterior WM atrophy. The distinct regional distribution of WM atrophy reflects the topography of gray matter (GM) loss. ApoE ε4 status is associated with a greater parahippocampal WM loss in AD. The greater WM atrophy in EOAD than in LOAD fits with the evidence that EOAD is a more aggressive form of the disease [62] . FDG-PET is quantitatively more accurate than perfusion SPECT.

Regional metabolic and blood flow changes are closely related to clinical symptoms, and most areas involved in these changes also develop significant cortical atrophy. FDG-PET is complementary to amyloid PET, which targets a molecular marker that does not have a close relation to current symptoms. FDG-PET is expected to play an increasing role in diagnosing patients at an early stage of AD and in clinical trials of drugs aimed at preventing or delaying the onset of dementia [63] . Functional neuroimaging biomarkers are becoming popular, with the introduction of novel tracers for brain amyloid deposits. Amyloid deposition causes severe damage to neurons many years before onset of dementia via a cascade of several downstream effects.

Positron emission tomography (PET) tracers for amyloid plaque are desirable for early diagnosis of AD, particularly to enable preventative treatment once effective therapeutics is available. The amyloid imaging tracers flutemetamol, florbetapir, and florbetaben labeled with 18 F have been developed for PET. These tracers are currently undergoing formal clinical trials to establish whether they can be used to accurately image fibrillary amyloid, and to distinguish patients with AD from normal controls and those with other diseases that cause dementia [63] .

There is a renewed interest in the use of computerized brain mapping as a diagnostic aid and as a monitoring tool in AD [64] . Electroencephalography (EEG) studies in AD show an attenuation of average power within the alpha band and an increase in power in the theta band (4-7 Hz) [65] . APOE genotypes influence brain bioelectrical activity in AD. In general, APOE-4 carriers tend to exhibit a slower EEG pattern from early stages [16, 18, 66] .

Other biomarkers of potential interest include cerebrospinal fluid (CSF) and peripheral levels of Aβ 42 , protein tau, histamine, interleukins, and some other novel candidate markers such as chitinase 3-like 1 (CHI3L1) protein [7, 16, 25, [67] [68] [69] . The concentration of the 42-amino-acid form of Aβ (Aβ 1-42 ) is reduced in the CSF of AD patients, which is believed to reflect the AD pathology, with plaques in the brain acting as sinks. Novel C-truncated forms of Aβ (Aβ 1-14 , Aβ 1-15 , and Aβ 1-16 ) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by βfollowed by α-secretase. Aβ 1-14 , Aβ 1-15 , and Aβ 1-16 increase dose-dependently in response to γ-secretase inhibitor treatment, while Aβ 1-42 levels are unchanged [70] .

Kester et al. [71] investigated change over time in CSF levels of amyloid-beta 40 and 42 (Aβ 40 and Aβ 42 ), total tau (tau), tau phosphorylated at threonine 181 (ptau-181), isoprostane, neurofilaments heavy (NfH) and neurofilaments light (NfL). Aβ 42 , tau, and tau phosphorylated at threonine 181 differentiated between diagnosis groups, whereas isoprostane, NfH, and NfL did not. In contrast, effects of follow-up time were found only for nonspecific CSF biomarkers: levels of NfL decreased, and levels of isoprostane, Aβ 40 , and tau increased over time. An increase in isoprostane was associated with progression of mild cognitive impairment in AD and with cognitive decline. Contrary to AD-specific markers, nonspecific CSF biomarkers show change over time, which potentially can be used to monitor disease progression in AD.

Structural markers are represented by SNPs in genes associated with AD, polygenic cluster analysis, and genome-wide studies (GWSs). Functional markers attempt to correlate genetic defects with specific phenotypes (genotype-phenotype correlations). In proteomic studies, several candidate CSF protein biomarkers have been assessed in neuropathologically confirmed AD, nondemented (ND) elderly controls, and non-AD dementias (NADD). Markers selected included apolipoprotein A-1 (ApoA1), hemopexin (HPX), transthyretin (TTR), pigment epithelium-derived factor (PEDF), Aβ 1-40 , Aβ 1-42 , total tau, phosphorylated tau, α-1 acid glycoprotein (A1GP), haptoglobin, zinc α-2 glycoprotein (Z2GP), and apolipoprotein E (ApoE). Concentrations of Aβ 1-42 , ApoA1, A1GP, ApoE, HPX, and Z2GP differed significantly among AD, ND, and NADD subjects. The CSF concentrations of these three markers distinguished AD from ND subjects with 84% sensitivity and 72% specificity, with 78% of subjects correctly classified.

By comparison, Aβ 1-42 alone gave 79% sensitivity and 61% specificity, with 68% of subjects correctly classified. For the diagnostic discrimination of AD from NADD, only the concentration of Aβ 1-42 was significantly related to diagnosis, with a sensitivity of 58% and a specificity of 86% [72] . Carrying the APOE-ε4 allele was associated with a significant decrease in CSF Aβ 1-42 concentrations in middle-aged and older subjects. In AD, Aβ 1-42 levels are significantly lower in APOEε4 carriers compared to noncarriers. These findings demonstrate significant age effects on CSF Aβ 1-42 and pTau181 across the lifespan, and also suggest that a decrease in Aβ 1-42 , but an increase in pTau181 CSF levels, is accelerated by the APOEε4 genotype in middleaged and older adults with normal cognition [73] .

Han et al. [74] carried out a GWAS to better define the genetic backgrounds of normal cognition, mild cognitive impairment (MCI), and AD in terms of changes in CSF levels of Aβ 1-42 , T-tau, and P-tau181P. CSF Aβ 1-42 levels decreased with APOE gene dose for each subject group. T-tau levels tended to be higher among AD cases than among normal subjects. CYP19A1 "aromatase" (rs2899472), NCAM2, and multiple SNPs located on chromosome 10 near the ARL5B gene demonstrated the strongest associations with Aβ 1-42 in normal subjects.

Two genes found to be near the top SNPs, CYP19A1 (rs2899472) and NCAM2 (rs1022442), have been reported as genetic factors related to the progression of AD. In AD subjects, APOE ε2/ε3 and ε2/ε4 genotypes were associated with elevated T-tau levels, and the ε4/ε4 genotype was associated with elevated T-tau and P-tau181P levels. Bloodbased markers reflecting core pathological features of AD in presymptomatic individuals are likely to accelerate the development of disease-modifying treatments.

Thambisetty et al. [75] performed a proteomic analysis to discover plasma proteins associated with brain Aβ burden in nondemented older individuals. A panel of 18 2DGE plasma protein spots effectively discriminated between individuals with high and low brain Aβ. Mass spectrometry identified these proteins, many of which have established roles in Aβ clearance, including a strong signal from ApoE. A strong association was observed between plasma ApoE concentration, and Aβ burden in the medial temporal lobe. Targeted voxel-based analysis localized this association to the hippocampus and entorhinal cortex. APOE ε4 carriers also showed greater Aβ levels in several brain regions relative to ε4 noncarriers. Both peripheral concentration of the ApoE protein and the APOE genotype may be related to early neuropathological changes in brain regions vulnerable to AD pathology even in the nondemented elderly.

Modern therapeutic strategies in AD are aimed at interfering with the main pathogenic mechanisms potentially involved in AD [7, 12, 16, 18, 23, 24, 28, [53] [54] [55] [56] [57] [58] [59] (Box 27.1). Starting in the early 1990s, the neuropharmacology of AD was dominated by acetylcholinesterase inhibitors, represented by tacrine, donepezil, rivastigmine, and galantamine [76] [77] [78] . Memantine, a partial NMDA antagonist, was introduced in the 2000s for the treatment of severe dementia [79] ; and the first clinical trials with immunotherapy, to reduce amyloid burden in senile plaques, were withdrawn due to severe ADRs [80, 81] . After the initial promise of βand γ-secretase inhibitors [82, 83] and novel vaccines [84, 85] devoid of severe side effects, during the past few years no relevant drug candidates have dazzled the scientific community with their capacity to halt disease progression; however, a large number of novel therapeutic strategies for the pharmacological treatment of AD have been postulated, with some apparent effects in preclinical studies (see Box 27.1).

There are two main modalities of immunotherapy for AD: (1) passive immunotherapy, with the administration of monoclonal Aβ-specific antibodies [86] ; and (2) active immunization with the Aβ 42 antigen [87, 88] or Aβ-conjugated synthetic fragments bound to a carrier protein, thus avoiding potential problems associated with mounting a T-cell response directly against Aβ [89] . A new approach-delivering Aβ 42 in a novel immunogen-adjuvant manner consisting of sphingosine-1-phosphate (S1P)containing liposomes, administered to APP/PS1 transgenic mice before and after the detection of AD-like pathology in the brain-has recently been developed [85] .

The results from this novel vaccine (EB101) indicate that active immunization significantly prevents and reverses the progression of AD-like pathology and also clears prototypical neuropathological hallmarks in transgenic mice. This new approach strongly induces T-cell, B-cell, and microglial immune response activation, avoiding the Th1 inflammatory reaction [90] .

The rationale for amyloid immunotherapy in AD [91] is based on the following assumptions: l β-amyloid plaques and their aggregated, proto-fibrillar, and oligomeric precursors contain immunologic neoepitopes that are absent from the full-length amyloid precursor protein (APP), as well as from its soluble proteolytic derivatives restricted to brain tissue; consequently, β-amyloid-based immunotherapies designed to selectively target pathologic neo-epitopes present on Aβ oligomers, protofibrils, or fibrils should not cause autoimmune disease in unaffected tissues throughout the organism l β-amyloid buildup precedes neurodegeneration and functional loss, and either the prevention of its formation or its removal can be expected to result in the slowing or the prevention of neurodegeneration l β-amyloid can cause the formation of neurofibrillary tangles in vivo and in vitro. The removal of β-amyloid, or the prevention of its buildup, has the potential not only to correct β-amyloid-related toxicity, but also to prevent the formation of neurofibrillary tangles l Conformational changes of endogenously occurring proteins and the formation of insoluble aggregates are commonly associated with neurodegeneration and brain disease, so the removal or prevention of these pathologic protein aggregates is also a therapeutic goal in the principle of immunotherapy l Immunotherapy works in experimental animals and in initial clinical trials: both active immunization and passive antibody transfer consistently reduce brain β-amyloid load, improve β-amyloid-related memory impairments, and protect neurons against degeneration in many independent experiments using different mouse models and primates [90] Since Aβ immunotherapy has a limited clearance effect of tau aggregates in dystrophic neurites, the development of an alternative therapy that directly targets pathological tau has become crucial. Increased levels of tau oligomers have been observed in the early stage of AD, prior to the detection of neurofibrillary tangles (NFT) formed by aggregation and accumulation of the microtubule-associated protein tau [92] . Several approaches have been taken to treat AD by targeting tau, such as the following:

1. The inhibition of tau hyperphosphorylation, by a kinase inhibitor of soluble aggregated tau formation, which also prevents related motor deficits [93] . 2. Activation of the proteolytic pathway, by the degrading action of calpain [94] and puromycin-sensitive aminopeptidase [95] . 3. The stabilization of microtubules, treating tauopathies by functionally binding and stabilizing microtubules with mt-binding protein tau [96] and paclitaxel, a drug proven effective in restoring affected axonal transport and motor impairments [97] . 4. Tau clearance by immunotherapy in this case, the tau active vaccination uses phosphorylated antigens of tau fragments associated with neurofibrillary tangles [98] that results in an efficient reduction of both soluble and insoluble tau active fragments, reducing phosphorylated NFTs in AD-like mouse brains.

Preclinical studies have shown clear evidence that Aβ immunization therapy provides protection and reverses the pathological effects of AD in transgenic mouse models [99] . This strategy seems to improve cognition performance [100] 

after Aβ 42 immunization, in addition to causing an effective reduction in Aβ pathology. A recent immunization study has proven that a fragment of the Aβ peptide bound to polylysines activates the immune response that diminishes AD-like pathology in APP transgenic mice. This result reinforces the notion that the immune-conjugate approach is an effective means of Aβ immunotherapy, and also that the entire Aβ peptide is not necessary for its efficacy. It is in accordance with the hypothesis that specific antibodies directed against the amino-terminal and/or central region of the amyloid peptide provide beneficial protection against amyloid pathology. Passive immunization studies have also been conducted with promising experimental results, showing that a humoral response alone, without Aβ cellular response, is sufficient to reduce the β-amyloid burden and reverse memory deficits [101] .

Among the drugs and vaccines currently under development to treat the pathological effects of AD, the most promising are bapineuzumab, solanezumab, CAD106, and EB101. Solanezumab is a monoclonal antibody raised against Aβ 13-28 that recognizes an epitope in the core of the amyloid peptide, binding selectively to soluble Aβ and with low affinity for the fibrillar Aβ form [102] . Thus, it presents fewer adverse events than does bapineuzumab, which binds to Aβ amyloid plaques more strongly than soluble Aβ [103] .

There are a few other monoclonal antibodies against Aβ that have properties different from those of bapineuzumab, such as PF-04360365, which specifically targets the free carboxyterminus of Aβ 1-40 , MABT5102A, which binds with equally high affinity to Aβ monomers, oligomers, and fibrils, and GSK933776A, which targets the N-terminus of Aβ.

Specific anti-Aβ antibodies are present in pooled preparations of intravenous immunoglobulin (IVIg or IGIV), which has already been approved by the FDA for the treatment of a variety of neurological conditions. Current results from these studies have shown that IVIg treatment may also be an efficacious alternative approach in the treatment of AD neuropathologies [90, 104] .

Avoiding both the strong Th1 effects of the QS-21 adjuvant and the T-cell epitopes at the C-terminus of Aβ, CAD106 consists of a short N-terminal fragment of Aβ attached to a virus-like particle, with no additional adjuvant [105] . This therapeutic agent is currently in phase II trials. Affiris is testing two short 6-amino-peptides (AD01, AD02), administered with aluminum hydroxide as adjuvant, that mimic the free N-terminus of Aβ and therefore cause cross-reactivity with the native peptide in phase I trials [106] . In terms of prevention and therapeutic treatment, the EB101 vaccine showed for the first time the effectiveness of combining a liposomal immunogen-adjuvant with an Aβ antigen to induce an effective immunological response combined with an anti-inflammatory effect in preclinical studies using APP/PS1 transgenic mice [85, 90] .

The EB101 vaccine immunization process has shown a marked positive effect as a preventive and therapeutic treatment, reducing amyloidosis-induced inflammation as an effective Th2 immunomodulator. Moreover, this vaccine proved to stimulate innate immunity and enable effective phagocytosis to clear amyloid and neurofibrillary tangles, which are among the major hallmarks of AD-like neuropathology observed. A few other vaccines are currently under development, and recent studies have opened up new perspectives in the immunization approach to AD pathology; in particular, gene-gun-mediated genetic immunization with the Aβ 42 gene [107] shows that self-tolerance can be broken in order to produce a humoral response to the Aβ 42 peptide with minimal cellular response.

AD patients may take 6-12 different drugs per day for the treatment of dementia-related symptoms, including memory decline (conventional antidementia drugs, neuroprotectants), behavioral changes (antidepressants, neuroleptics, sedatives, hypnotics), and functional decline. Such drugs may also be taken for the treatment of concomitant pathologies (epilepsy, cardiovascular and cerebrovascular disorders, parkinsonism, hypertension, dyslipidemia, anemia, arthrosis, etc). The co-administration of several drugs may cause side effects and ADRs in more than 60% of AD patients, who in 2-10% of cases require hospitalization. In more than 20% of patients, behavioral deterioration and psychomotor function can be severely altered by polypharmacy. The principal causes of these iatrogenic effects are (1) the inappropriate combination of drugs, and (2) the genomic background of the patient, which is responsible for his/her pharmacogenomic outcome.

Pharmacogenomics account for 30-90% of the variability in pharmacokinetics and pharmacodynamics. The genes involved in the pharmacogenomic response to drugs in AD fall into five major categories: 

In more than 100 clinical trials for dementia, APOE has been used as the only gene of reference for the pharmacogenomics of AD [7, 12, 15, 16, [22] [23] [24] [25] [26] [27] [28] [53] [54] [55] [56] [57] [58] [59] . Several studies indicate that the presence of the APOE-4 allele differentially affects the quality and extent of drug responsiveness in AD patients treated with cholinergic enhancers (tacrine, donepezil, galantamine, rivastigmine), neuroprotective compounds (nootropics), endogenous nucleotides (CDPcholine), immunotrophins (anapsos), neurotrophic factors (cerebrolysin), rosiglitazone, or combination therapies [108] [109] [110] ; however, controversial results are frequently found that are due to methodological problems, study design, and patient recruitment in clinical trials.

The major conclusion in most studies is that APOE-4 carriers are the worst responders to conventional treatments [7, 12, 15, 16, [22] [23] [24] [25] [26] [27] [28] [53] [54] [55] [56] [57] [58] [59] . When APOE and CYP2D6 genotypes are integrated in bigenic clusters and the APOE+CYP2D6-related therapeutic response to a combination therapy is analyzed in AD patients, it becomes clear that the presence of the APOE-4/4 genotype is able to convert pure CYP2D6*1/*1 extensive metabolizers (EMs) into full poor responders to conventional treatments, indicating the existence of a powerful influence of the APOE-4 homozygous genotype on the drug-metabolizing capacity of pure CYP2D6 EMs. In addition, a clear accumulation of APOE-4/4 genotypes is observed among CYP2D6 poor (PMs) and ultrarapid metabolizers (UMs) [12] .

Most genes associated with the mechanism of action of CNS drugs encode receptors, enzymes, and neurotransmitters on which psychotropic drugs act as ligands (agonists, antagonists), enzyme modulators (substrates, inhibitors, inducers), or neurotransmitter regulators (releasers, reuptake inhibitors) [111] . In the case of conventional antidementia drugs, tacrine, donepezil, rivastigmine and galantamine are cholinesterase inhibitors, and memantine is a partial NMDA antagonist (Table 27 .1).

Drug metabolism includes phase I reactions (i.e., oxidation, reduction, hydrolysis) and phase II conjugation reactions (i.e., acetylation, glucuronidation, sulphation, methylation) (Table 27 .2). The principal enzymes with polymorphic variants involved in phase I reactions are the following: cytochrome P450 monooxygenases (CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2), epoxide hydrolase, esterases, NQO1 (NADPH-quinone oxidoreductase), DPD (dihydropyrimidine dehydrogenase), ADH (alcohol dehydrogenase), and ALDH (aldehyde dehydrogenase). The major enzymes involved in phase II reactions include UGTs (uridine 5ʹ-triphosphate glucuronosyl transferases), TPMT (thiopurine methyltransferase), COMT (catechol-O-methyltransferase), HMT ( histamine methyl-transferase), STs (sulfotransferases), GST-A (glutathione S-transferase A), GST-P, GST-T, GST-M, NAT1 (N-acetyl transferase 1), NAT2, and others (Table 27.2) .

Among these enzymes, CYP2D6, CYP2C9, CYP2C19, and CYP3A4/5 are the most relevant in the pharmacogenetics of CNS drugs [15, 111] (Table 27 .1). Approximately 18% of neuroleptics are major substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are major substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are major substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4 [15, 111] . Most CYP enzymes exhibit ontogenic-, age-, sex-, circadian-, and ethnic-related differences [112] .

In dementia, as in any other CNS disorder, CYP genomics is a very important issue, since in practice more than 90% of patients with dementia are daily consumers of psychotropics. Furthermore, some acetylcholinesterase inhibitors (the most prescribed antidementia drugs worldwide) are metabolized via CYP enzymes (Table 27 .1). Most CYP enzymes display highly significant ethnic differences, indicating that the enzymatic capacity of these proteins varies depending upon the polymorphic variants present in their coding CYP genes.

The practical consequence of this genetic variation is that the same drug can be differentially metabolized according to the genetic profile of each subject, and that, if an individual's pharmacogenomic profile is known, his/ her pharmacodynamic response is potentially predictable. This is the cornerstone of pharmacogenetics. In this regard, the CYP2D6, CYP2C19, CYP2C9, and CYP3A4/5 genes and their respective protein products deserve special consideration.

CYP2D6 is a 4.38 kb gene with 9 exons mapped on 22q13.2. Four RNA transcripts of 1190-1684 bp are expressed in the brain, liver, spleen, and reproductive system, where 4 major proteins of 48-55 kDa (439-494 aa) are identified. It is a transport enzyme of the cytochrome P450 subfamily IID or multigenic cytochrome P450 superfamily of mixed-function monooxygenases. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. CYP2D6 localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs, and more than 60% of current psychotropics. Its substrates include debrisoquine, an adrenergic-blocking drug; sparteine and propafenone, both antiarrhythmic drugs; and amitryptiline, an antidepressant. CYP2D6 is highly polymorphic in the population. There are 141 CYP2D6 allelic variants, of which -100C > T, -1023C > T, -1659G > A, -1707delT, -1846G > A, -2549delA, -2613-2615delAGA, -2850C > T, -2988G > A, and -3183G > A represent the ten most important [113] [114] [115] . Different alleles result in the extensive, intermediate, poor, and ultrarapid metabolizer phenotypes, characterized by normal, intermediate, decreased, and multiplied ability to metabolize the enzyme's substrates, respectively. The hepatic cytochrome P450 system is responsible for the first phase in the metabolism and elimination of numerous endogenous and exogenous molecules and ingested chemicals. P450 enzymes convert these substances into electrophilic intermediates, which are then conjugated by phase II enzymes (e.g., UDP glucuronosyltransferases, N-acetyltransferases) to hydrophilic derivatives that can be excreted. According to the database of the World Guide for Drug Use and Pharmacogenomics [113] , 982 drugs are CYP2D6-related: 371 are substrates, more than 300 are inhibitors, and 18 are CYP2D6 inducers.

In healthy subjects, extensive metabolizers (EMs) account for 55.71% of the population; intermediate metabolizers (IMs) account for 34.7%; poor metabolizers (PMs), 2.28%; and ultrarapid metabolizers (UMs), 7.31%. Remarkable worldwide interethnic differences exist in the frequency of the PM and UM phenotypes [116] [117] [118] . On average, approximately 6.28% of the world's population belongs to the PM category. Europeans (7.86%), Polynesians (7.27%), and Africans (6.73%) show the highest rate of PMs, whereas Orientals (0.94%) show the lowest [116] . The frequency of PMs among Middle Eastern populations, Asians, and Americans is in the range of 2-3%. CYP2D6 gene duplications are relatively infrequent among Northern Europeans, but in East Africa the frequency of alleles with duplication of CYP2D6 is as high as 29% [119] . In Europe, there is a North-South gradient in the frequency of PMs (6-12% of PMs in Southern European countries, and 2-3% of PMs in Northern latitudes) [111] .

In AD, EMs, IMs, PMs, and UMs are 56.38%, 27.66%, 7.45%, and 8.51%, respectively, and in vascular dementia, they are, respectively, 52.81%, 34.83%, 6.74%, and 5.62% (Figure 27.3) . There is an accumulation of AD-related risk genes in PMs and UMs. EMs and IMs are the best responders, and PMs and UMs are the worst responders to a combination therapy of cholinesterase inhibitors, neuroprotectants, and vasoactive substances. The pharmacogenetic response in AD appears to depend on the networking activity of genes involved in drug metabolism and genes involved in AD pathogenesis [7, 12, 15, 16, [22] [23] [24] [25] [26] [27] [28] [53] [54] [55] [56] [57] [58] [59] .

CYP2C9 is a gene (50.71 kb) with 9 exons mapped on 10q24. An RNA transcript of 1860 bp is mainly expressed in hepatocytes, where a protein of 55.63 kDa (490 aa) can be identified. More than 600 drugs are CYP2C9-related: 311 act as substrates (177 major, 134 minor); 375, as inhibitors (92 weak, 181 moderate, and 102 strong); and 41 as inducers of the CYP2C9 enzyme [113] . There are 481 CYP2C9 SNPs. By phenotype (Figure 27.4) , in the control population, PMs represent 7.04%, IMs 32.39%, and EMs 60.56%. In AD, PMs, IMs, and EMs are 6.45%, 37.64%, and 55.91%, respectively, and in vascular dementia they are 3.61%, 28.92%, and 67.47%, respectively [18] (Figure 27.4) . CYP3A4 metabolizes more than 1900 drugs: 1033 act as substrates (897 major, 136 minor); 696, as inhibitors (118 weak, 437 moderate, and 141 strong); and 241, as inducers of the CYP3A4 enzyme [113] . About 347 SNPs have been identified in the CYP3A4 gene (CYP3A4*1A: wildtype), 25 of which are of clinical relevance. Concerning CYP3A4/5 polymorphisms in AD, 82.75% of cases are EMs (CYP3A5*3/*3), 15.88% are IMs (CYP3A5*1/*3), and 1.37% are UMs (CYP3A5*1/*1). Unlike other human P450s (CYP2D6, CYP2C19) , there is no evidence of a "null" allele for CYP3A4 [113] . 

The construction of a genetic map integrating the most prevalent CYP2D6+CYP2C19+CYP2C9 polymorphic variants in a trigenic cluster yields 82 different haplotype-like profiles. The most frequent trigenic genotypes in the AD population are *1*1-*1*1-*1*1 (25.70%), *1*1-*1*2-*1*2 (10.66%), *1*1-*1*1-*1*1 (10.45%), *1*4-*1*1-*1*1 (8.09%), *1*4-*1*2-*1*1 (4.91%), *1*4-*1*1-*1*2 (4.65%), and *1*1-*1*3-*1*3 (4.33%). These 82 trigenic genotypes represent 36 different pharmacogenetic phenotypes.

According to these trigenic clusters, only 26.51% of patients show a pure 3EM phenotype, 15.29% are 2EM1IM, 2.04% are pure 3IM, 0% are pure 3PM, and 0% [18] . are 1UM2PM (the worst possible phenotype). This implies that only one-quarter of the population normally process the drugs that are metabolized via CYP2D6, CYP2C9, and CYP2C19 (approximately 60% of the drugs in current use) [12] . Taking into consideration the data available, it might be inferred that at least 20-30% of the AD population may exhibit an abnormal metabolism of cholinesterase inhibitors and/or other drugs that undergo oxidation via CYP2D6related enzymes.

Approximately 50% of this population cluster shows an ultrarapid metabolism, requiring higher doses of cholinesterase inhibitors in order to reach a therapeutic threshold. The other 50% of the cluster exhibit a poor metabolism, displaying potential adverse events at low doses. If we take into account that approximately 60-70% of therapeutic outcomes depend on pharmacogenomic criteria (e.g., pathogenic mechanisms associated with AD-related genes), it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75-85% of therapeutic response (efficacy) in AD patients treated with conventional drugs [12, [15] [16] [17] [18] [22] [23] [24] [25] 28, [53] [54] [55] [56] [57] [58] [59] .

ABC genes-especially ABCB1 (ATP-binding cassette, subfamily B, member 1P-glycoprotein-1, P-gp1, Multidrug Resistance 1, MDR (17q21.12), ABCC1 (9q31.1), ABCG2 (White121q22.3), and other genes of this family-encode proteins that are essential for drug metabolism and transport. The multidrug efflux transporters P-gp, the multidrug resistance-associated protein 4 (MRP4), and the breast cancer resistance-protein (BCRP), located on endothelial cells lining the brain vasculature, play important roles in limiting the movement of substances into the brain and in enhancing their efflux from the brain.

Transporters also cooperate with phase I/phase II metabolism enzymes by eliminating drug metabolites. Their major features are their capacity to recognize drugs belonging to unrelated pharmacological classes and their redundancy, by which a single molecule can act as a substrate for different transporters. This ensures efficient neuroprotection against xenobiotic invasions. The pharmacological induction of ABC gene expression is a mechanism of drug interaction, which may affect substrates of the upregulated transporter; overexpression of MDR transporters confers resistance to anti-cancer agents and CNS drugs [120, 121] .

Also of importance for CNS pharmacogenomics are transporters encoded by genes of the solute carrier superfamily (SLC) and solute carrier organic (SLCO) transporter family, which are responsible for the transport of multiple endogenous and exogenous compounds, including folate (SLC19A1), urea (SLC14A1, SLC14A2), monoamines (SLC29A4, SLC22A3), aminoacids (SLC1A5, SLC3A1, [122] .

Some organic anion transporters (OAT), which belong to the solute carrier (SLC) 22A family, are also expressed at the BBB, and regulate the excretion of endogenous and exogenous organic anions and cations [123] . The transport of amino acids and di-and tripeptides is mediated by a number of different transporter families, and the bulk of oligopeptide transport is attributable to the activity of members of the SLC15A superfamily (peptide transporters 1 and 2 (SLC15A1[PepT1]) and SLC15A2[PepT2], and peptide/histidine transporters 1 and 2 (SLC15A4[PHT1] and SLC15A3[PHT2]). ABC and SLC transporters expressed at the BBB may cooperate to regulate the passage of different molecules into the brain [124] . Polymorphic variants in ABC and SLC genes may also be associated with pathogenic events in CNS disorders and drug-related safety and efficacy complications [111, 122] .

APOE is the prototypical paradigm of a pleiotropic gene with multifaceted activities in physiological and pathological conditions [16, 22] . ApoE is consistently associated with the amyloid plaque marker for AD. APOE-4 may influence AD pathology interacting with APP metabolism and Aβ accumulation, enhancing hyperphosphorylation of tau protein and NFT formation, reducing choline acetyltransferase activity, increasing oxidative processes, modifying inflammation-related neuroimmunotrophic activity and glial activation, altering lipid metabolism, lipid transport, and membrane biosynthesis in sprouting and synaptic remodeling, and inducing neuronal apoptosis [16, [23] [24] [25] .

To address the complex misfolding and aggregation that initiates the toxic cascade resulting in AD, Petrlova et al. [26] developed a 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid spin-labeled amyloid-β (Aβ) peptide to observe its isoform-dependent interaction with the ApoE protein. Oligomer binding involves the C-terminal domain of ApoE, with ApoE3 reporting a much greater response through this conformational marker. ApoE3 displays a higher affinity and capacity for the toxic Aβ oligomer. ApoE polymorphism and AD risk can largely be attributed to the reduced ability of ApoE4 to function as a clearance vehicle for the toxic form of Aβ. MAPT and APOE are involved in the pathogenic mechanisms of AD, and both the MAPT H1/H1 genotype and the APOE ε4 allele lead to a more rapid progression to dementia among MCI subjects, probably mediating an increased rate of amyloid-β and tau brain deposition [27] .

The distribution of APOE genotypes in the Iberian peninsula is as follows: APOE-2/2 0.32%; APOE-2/3 7.3%; APOE-2/4 1.27%; APOE-3/3 71.11%; APOE-3/4 18.41%; and APOE-4/4 1.59% [18] (Figure 27 .2). These frequencies are very similar in Europe and in other Western societies. There is a clear accumulation of APOE-4 carriers among patients with AD (APOE-3/4 30.30%, APOE-4/4 6.06%) and vascular dementia (APOE-3/4 35.85%, APOE-4/4 6.57%) as compared to controls (Figure 27 .2). Different APOE genotypes confer specific phenotypic profiles to AD patients [15, 16, 22] . Some of these profiles may add risk or benefit when patients are treated with conventional drugs, and in many instances the clinical phenotype demands the administration of additional drugs that increase the complexity of therapeutic protocols.

From studies designed to define APOE-related AD phenotypes [7, 12, [23] [24] [25] 28, [53] [54] [55] [56] [57] [58] [59] , several conclusions can be drawn, which are shown in Box 27.2. These 20 major phenotypic features clearly illustrate the biological disadvantage of APOE-4 homozygotes and the potential consequences that these patients may experience when they receive pharmacological treatment for AD and/or concomitant pathologies [7, 12, [23] [24] [25] 28, [53] [54] [55] [56] [57] [58] [59] .

The following list describes the pharmacogenomics of the most common antidementia drugs (Table 27. 

Donepezil: is a centrally active, reversible acetylcholinesterase inhibitor that increases the acetylcholine available for synaptic transmission in the CNS. The therapeutic response of donepezil is influenced by pathogenic gene variants (APOE, CHAT), as well as mechanistic gene polymorphic variants (CHAT, ACHE, and BCHE). It is a major substrate of CYP2D6, CYP3A4, ACHE, and UGTs; it inhibits ACHE and BCHE; and it is transported by ABCB1 [113] .

Galantamine: is a reversible and competitive acetylcholinesterase inhibitor leading to increased concentration of acetylcholine at cholinergic synapses. It also modulates nicotinic acetylcholine receptors and may increase glutamate and serotonin levels. APOE, APP, ACHE, BCHE, CHRNA4, CHRNA7, and CHRNB2 variants may potentially influence galantamine efficacy and safety. Galantamine is a major substrate of CYP2D6, CYP3A4, and UGT1A1, and an inhibitor of ACHE and BCHE [113] .

of AD cases harboring the APOE-4/4 genotype. 

wave activity in APOE-4/4 from the early stages of the disease. 12. Brain hemodynamics, as reflected by reduced brain blood flow velocity and increased pulsatility and resistance indices, is significantly worse in APOE-4/4 (and in APOE-4 carriers in general, as compared with APOE-3 carriers); brain hypoperfusion and neocortical oxygenation is also more deficient in APOE-4 carriers.

carriers. 

Rivastigmine: is a cholinesterase inhibitor that increases acetylcholine in the CNS through reversible inhibition of its hydrolysis by cholinesterase. APOE, APP, CHAT, ACHE, BCHE, CHRNA4, CHRNB2, and MAPT variants may affect its pharmacokinetics and pharmacodynamics [113] .

Tacrine: is the first FDA-approved antidementia drug. Its use was stopped due to hepatotoxicity. Tacrine is a cholinesterase inhibitor that elevates acetylcholine in the cerebral cortex by slowing degradation of acetylcholine. ACHE, BCHE, CHRNA4, CHRNB2, APOE, MTHFR, CES1, LEPR, GSTM1, and GSTT1 variants may affect its therapeutic and toxic effects. Tacrine is a major substrate of CYP1A2 and CYP3A4, a minor substrate of CYP2D6, and is transported via SCN1A. It is an inhibitor of ACHE, BCHE, and CYP1A2 [113] .

Memantine: is an N-Methyl-D-Aspartate (NMDA) receptor antagonist that binds preferentially to NMDA receptor-operated cation channels. It may act by blocking the actions of glutamate, mediated in part by NMDA receptors, and it is also an antagonist of GRIN2A, GRIN2B, GRIN3A, HTR3A, and CHRFAM7A. Several pathogenic (APOE, PSEN1, MAPT) and mechanistic gene variants (GRIN2A, GRIN2B, GRIN3A, HTR3A, CHRFAM7A) may influence its therapeutic effects. Memantine is a strong inhibitor of CYP2B6 and CYP2D6, and a weak inhibitor of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 [113] .

Some studies using a multifactorial approach also have shown that diverse pharmacogenomic factors may influence efficacy and safety. In one of these studies [15, 58] , patients with dementia received the following for three months: Patients with chronic deficiencies of iron (<35 μg/mL), folic acid (<2.5 ng/mL), or vitamin B 12 (<150 pg/mL) received an additional supplement of iron (80 mg/day), folic acid (5 mg/day), and B complex vitamins (B 1 , 15 mg/ day; B 2 , 15 mg/day; B 6 , 10 mg/day; B 12 , 10 μg/day; nicotinamide, 50 mg/day), respectively, to maintain stable levels of serum iron (50-150 μg/mL), folic acid (5-20 ng/mL) and vitamin B 12 levels (500-1000 pg/mL) in order to avoid the negative influence of all these metabolic factors on cognition. Patients with hypertension (>150/85 mmHg) received Enalapril (20 mg/day). 

In this study, the basal MMSE score differed in APOE-2/3 carriers with respect to APOE-2/4 (p < 0.02), APOE-3/4 (p < 0.004), and APOE-4/4 (p < 0.0009), in APOE-3/3 vs. APOE-3/4 (p < 0.0005), and in APOE-3/3 vs. APOE-4/4 (p < 0.002). The best responders were APOE-3/3 (p < 0.0000000001) >APOE-3/4 (p < 0.00001) >APOE-4/4 carriers (p < 0.05). Patients harboring the APOE-2/3 and APOE-2/4 genotypes did not show any significant improvement. The response rate by genotype was the following: APOE-2/3: 44 

Systolic blood pressure (SBP) was significantly reduced in patients with the APOE-3/3 (p < 0.00007) and APOE-3/4 genotypes (p < 0.01), and diastolic blood pressure exhibited a similar pattern (APOE-3/3, p < 0.005; APOE-3/4, [15] .

HDL-cholesterol levels significantly decreased in APOE-3/3 (p < 0.001) > APOE-3/4 (p < 0.05), with no significant changes in patients with other genotypes. In contrast, LDL-cholesterol levels showed changes identical to those observed in total cholesterol, with similar differences among genotypes at baseline and almost identical decreased levels after treatment (APOE-3/3, p > 0.0000000001 >APOE-3/4, p < 0.00001 >APOE-2/3, p < 0.0004 >APOE-4/4, p < 0.001 > APOE-2/4, p:0.31) [15] .

Sardilipin (E-SAR-94010, LipoEsar®, LipoSea®) is a natural product extracted from the marine species Sardina pilchardus by means of nondenaturing biotechnological procedures. The main chemical compounds of LipoEsar® are lipoproteins (60-80%), whose micelle structure probably mimics that of physiological lipoproteins involved in lipid metabolism. In preclinical studies, Sardilipinhas been shown to be effective in:

1. Reducing blood cholesterol (CHO), triglyceride (TG), uric acid (UA), and glucose (Glu) levels, as well as liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity.

lymphocyte and microglia activity. 3. Inducing antioxidant effects mediated by superoxide dismutase activity. 4. Improving cognitive function [15] .

According to these results, it appears that the therapeutic response of patients with dyslipidemia to Sardilipin is APOE-related. The best responders were patients with APOE-3/3 >APOE-3/4 >APOE-4/4. Patients with the other APOE genotypes (2/2, 2/3, 2/4) did not show any hypolipidemic response to this novel compound. In patients with dementia, the effects of Sardilipin were very similar to those observed in patients with chronic dyslipidemia, suggesting that the lipid-lowering properties of Sardilipin are APOE-dependent [15] (Figure 27.8 ).

To make AD a global health priority in the coming years, conceptual and procedural changes are needed on several grounds, such as (1) political, administrative, economic, legal, ethical, industrial, regulatory and educational issues; (2) novel biomarkers (genomics, proteomics, molecular neuroimaging) as diagnostic aids; (3) innovative therapeutics; (4) pharmacogenomics in clinical practice to optimize therapeutics; and (5) selective preventive plans for the population at risk.

There is disharmony concerning the public and governmental interest in dementia and its social, medical, and economic implications. The diagnosis and management of dementia is dissimilar in Europe, North America, Latin America, Asia, Africa, and Oceania. The economic/cultural status of each country (developed versus developing), the [15] . particular epidemiology of aging and dementia in each latitude, national standards of education, health priorities (infectious diseases versus degenerative diseases), and the quality and efficiency of medical services are conditioning factors for investing (or not investing) national resources in dementia as a health priority.

Educational programs, international guidelines, and consensus protocols for the management of dementia are necessary for global harmonization, for professionals from different countries to speak the same conceptual language, and to improve cost-effectiveness ratios [125] [126] [127] [128] . There are many legal issues (e.g., informed consent, lawsuit, testament, tutorship) and ethical issues (e.g., clinical trials, use of genetic information, institutionalization) that deserve more attention in order to humanize the end of life in the very frail conditions under which demented patients survive.

The updating of regulatory issues is also a matter of deep concern. Regulatory aspects of drug development are not universal, with notable peculiarities in the European Union (EMA), the United States (FDA), and Japan (Koseisho). Because the costs of dementia cannot be fully assumed by more than 60% of the European population, European authorities must take into account this circumstance when health reform is implemented in the coming years [8, 18] .

Genomics, transcriptomics, proteomics, and metabolomics will revolutionize medicine in the next decades. Genetic testing is gaining acceptance among physicians and patients in different countries [128] [129] [130] [131] , although Americans, Europeans, and Japanese differ notably in their knowledge, beliefs, and attitudes regarding genetic testing for AD [128, 131, 132] . The validation of protocols for genomic screening will contribute to the implementation of structural genomics, functional genomics, and proteomics as diagnostic aids and therapeutic targets [133] .

An accurate diagnosis of AD demands the use of reliable biomarkers in routine protocols at a reasonable price [68] . Levels of specific secreted cellular signaling proteins in cerebrospinal fluid or plasma correlate with pathological changes in the AD brain; therefore, proteomic analysis of these levels can be used to discover said biomarkers [134] . It is likely that the best biomarkers result from a combination of genomic, transcriptomic, and proteomic analyses of body fluids. The measurement of these biomarkers correlates with brain imaging markers and cognitive performance [73] [74] [75] .

New initiatives for the prevention of dementia (global versus selective prevention) will also emerge [135] , together with new insights into the role of nutrition and nutrigenomics in brain function and neurodegeneration [59, 136] . In terms of prevention, it must be taken into consideration that neuronal death and Aβ accumulation starts many years before the onset of the disease, and that preventive strategies should be selective to protect the population at risk.

For this purpose, accurate biomarkers are essential, and surrogate markers are needed to facilitate primary prevention.

Without doubt, the highest priority for the coming decade will be an intense search for novel therapeutic options in the form of both symptomatic treatments and preventive strategies. Past failures must be studied by researchers and the pharmaceutical industry in order to avoid unnecessary expenses in redundant trials that lead nowhere. Combination treatments require further evaluation and more sophisticated strategies than dual combinations [137, 138] . The administration of psychotropic drugs to demented patients should be reduced and predicted with pharmacogenetic markers to minimize side effects, cerebrovascular risk, and cognitive deterioration.

Priority areas for pharmacogenetic research are the prediction of serious adverse drug reactions (ADRs) and the determination of efficacy variation [139] . Both are necessary in CNS disorders and dementia to cope with efficacy and safety issues associated with current psychotropics and antidementia drugs, as well as new CNS drugs. With regard to the future of pharmacogenomics as a practical discipline, several issues should be addressed: l The education of physicians in medical genomics and pharmacogenomics is fundamental (less than 2% of clinicians are familiar with genomic science) l Genomic screening of gene clusters involved in pharmacogenomic outcomes must become a clinical routine (without genetic testing, there is no pharmacogenetics) l Each patient must be a carrier of a pharmacogenetic card [140] indicating what kind of drugs he/she can take and which medications he/she should avoid l Regulatory agencies should request pharmacogenetic data from the pharmaceutical industry when applying for drug approval l Pharmacogenetic data must be incorporated into patient information leaflets and the pharmaceutical vade mecum l New guidelines for daily praxis, such as those given in the World Guide for Drug Use and Pharmacogenomics [113] , will promote understanding of the relationship between drugs and genes to make drug prescription truly personalized

AD is a major health problem that comes with a high cost to society. As a clinical entity, AD is a polygenic/complex disorder in which many different gene clusters may be involved. Most genes screened to date belong to different proteomic and metabolomic pathways that potentially affect AD pathogenesis, represented by accumulation of Aβ deposits in senile plaques, intracellular NFTs with hyperphosphorylated tau, and neuronal loss.

The presence of the APOE-4 allele of the apolipoprotein E gene seems to be a major risk factor for both degenerative and vascular dementia, and APOE variants are directly involved in AD pathogenesis at multiple levels. Specific biomarkers (structural and functional genomic markers, proteomic markers in body fluids, neuroimaging markers) are needed for an accurate AD diagnosis. Current pharmacological treatment of AD with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine is not cost-effective; moreover, the overuse of psychotropic drugs in patients with dementia contributes to deteriorating cognitive and psychomotor functions.

Old treatments addressed memory impairment. New treatments are oriented to halting disease progression by interfering with Aβ accumulation, NFT formation, oxidative stress, neuroinflammation, and cerebrovascular damage. Over the past few years diverse candidate drugs have been investigated in AD models, but not one has reached the market. Since only 25-30% of the population is an extensive metabolizer for drugs metabolized via CYP2D6, CYP2C9, and CYP2C19 enzymes, it seems reasonable to use pharmacogenomic procedures as a way to optimize AD therapeutics, thus reducing ADRs and unnecessary costs. The therapeutic response to conventional drugs in patients with AD is genotype-specific, with CYP2D6-PMs, CYP2D6-UMs, and APOE-4/4 carriers shown to be the worst responders. APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function.

If we know the pharmacogenomic profiles of patients who require treatment with antidementia drugs and/or psychotropic drugs currently in use, we may be able to achieve the following benefits: l Identifying candidate patients with the ideal genomic profile to receive a particular drug l Adapting the dose in more than 90% of cases according to the condition of EM, IM, PM, or UM, which will limit the occurrence of direct side effects in 30-50% of cases l Reducing drug interactions by 30-50% (avoiding the administration of inhibitors or inducers able to modify the normal enzymatic activity on a particular substrate) l Enhancing efficacy l Eliminating unnecessary costs (>30% of pharmaceutical direct costs) deriving from the consequences of inappropriate drug selection and overmedication to mitigate ADRs [18] APPENDIX A 

The clinical and economic burden of newly diagnosed Alzheimer's disease in a medicare advantage population

With special feature on medical technology

Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey

The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada

The path to personalized medicine in mental disorders

The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project

The GERAS study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries: study design and baseline findings

Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data

All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study

Pharmacogenomics and therapeutic strategies for dementia

High throughput protein expression screening in the nervous system-needs and limitations

Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender

Future trends in the pharmacogenomics of brain disorders and dementia: influence of APOE and CYP2D6 variants

Molecular genetics of Alzheimer's disease and aging

Alzheimer Research Forum

Alzheimer's disease 2011: where are we heading?

Deciphering the genetic basis of Alzheimer's disease

Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Apolipoprotein E and central nervous system disorders: reviews of clinical findings

Pharmacogenomics in Alzheimer's disease

Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease

The application of functional genomics to Alzheimer's disease

A differential association of apolipoprotein E isoforms with the amyloid-β oligomer in solution

The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia

Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics

A complex crosstalk between polymorphic microRNA target sites and AD prognosis

Advances in epigenetics and epigenomics for neurodegenerative diseases

MicroR-NAs in brain development and degeneration

Vascular and metabolic dysfunction in Alzheimer's disease: a review

Role of cardiovascular risk factors (CRF) in the patients with mild cognitive impairment (MCI)

Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of Alzheimer's disease

Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease

Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer

Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases

Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications

Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component

Regional white matter hyperintensities in normal aging, single domain amnestic mild cognitive impairment, and mild Alzheimer's disease

Cerebral amyloid angiopathy-related microhemorrhages in Alzheimer's disease: a review of investigative animal models

Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease

Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice

Disturbed neurotransmitter transporter expression in Alzheimer's disease brain

Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion

Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β

Decreased proteolytic activity of the mitochondrial amyloid-β degrading enzyme, PreP peptidasome, in Alzheimer's disease brain mitochondria

Alzheimer's disease: cholesterol a menace?

Molecular dynamics simulations reveal the protective role of cholesterol in beta amyloid protein-induced membrane disruptions in neuronal membrane mimics

Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease

Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease

Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease

Genomics and pharmacogenomics of dementia

Pharmacogenomics and therapeutic prospects in Alzheimer's disease

Pharmacogenomics and therapeutic prospects in dementia

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics

Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression

Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease

The pathological process underlying Alzheimer's disease in individuals under thirty

Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study

Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage

Clinical amyloid imaging in Alzheimer's disease

Improving the specificity of EEG for diagnosing Alzheimer's disease

Region and frequency specific changes of spectral power in Alzheimer's disease and mild cognitive impairment

Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study

Genomics and phenotypic profiles in dementia: implications for pharmacological treatment

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Histamine in Alzheimer's disease pathogenesis: biochemistry and functional genomics

Novel Aβ isoforms in Alzheimer's disease -their role in diagnosis and treatment

Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers

Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease

Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype

Alzheimer's disease neuroimaging initiative. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics

Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disordersp

Memantine in moderate-to-severe Alzheimer's disease

Aβ immunotherapy: lessons learned for potential treatment of Alzheimer's disease

Vaccination as a therapeutic approach to Alzheimer's disease

The secretases: enzymes with therapeutic potential in Alzheimer disease

Modulation of gamma-secretase specificity using small molecule allosteric inhibitors

DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse mode

Development of the EuroEspes EB101 vaccine against Alzheimer's disease

Amyloid-beta immunisation for Alzheimer's disease

Current therapeutic strategy in Alzheimer's disease

Current therapeutic targets for the treatment of Alzheimer's disease

Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies

Novel immunotherapeutic procedures for prevention of Alzheimer's disease

Immunotherapy against amyloid pathology in Alzheimer's disease

Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease

Tau as a therapeutic target for Alzheimer's disease

Tau phosphorylation and proteolysis: insights and perspectives

Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) doubletransgenic mice

Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

Alzheimer disease: amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease

Clinical trials in Alzheimer's disease': immunotherapy approaches

Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease)

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics

Pharmacogenomics of central nervous system (CNS) drugs

Molecular basis of ethnic differences in drug disposition and response

World guide for drug use and pharmacogenomics

The human cytochrome P450 (CYP) allele nomenclature database

Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population

PM frequencies of major CYPs in Asians and Caucasians

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1

Pharmacogenetics and pharmacogenomics: development, science, and translation

ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions

Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition

The metabolomics paradigm of pharmacogenomics in complex disorders

Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins

ABC and SLC transporter expression and Pot substrate characterization across the human CMEC/D3 bloodbrain barrier cell line

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention

Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility

Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the hisayama study

Differences between African American and white research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease

Proteomics in animal models of Alzheimer's and Parkinson's disease

Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium

Role of nutrition in the prevention of Alzheimer's disease

Combination therapy for Alzheimer's disease

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil

Priorities and standards in pharmacogenetic research

The EuroEspes pharmacogenetic card. Personalization in pharmacological treatment

Aldehyde dehydrogenase family 1, subfamily A2 ALDH1A3:Aldehyde dehydrogenase family 1, subfamily A3 ALDH1B1:Aldehyde dehydrogenase 1 family, member B1 ALDH2:Aldehyde dehydrogenase 2 family (mitochondrial) ALDH3A1:Aldehyde dehydrogenase 3 family, member A1 ALDH3A2:Aldehyde dehydrogenase 3 family, member A2 ALDH3B1:Aldehyde dehydrogenase 3 family, member B1 ALDH3B2:Aldehyde dehydrogenase 3 family, member B2 ALDH4A1:Aldehyde dehydrogenase 4 family, member A1 ALDH5A1:Aldehyde dehydrogenase 5 family, member A1 ALDH6A1:Aldehyde dehydrogenase 6 family, member A1 ALDH7A1:Aldehyde dehydrogenase 7 family, member A1 ALDH8A1:Aldehyde dehydrogenase 8 family, member A1 ALDH9A1:Aldehyde dehydrogenase 9 family, member A1 AOX1:Aldehyde oxidase 1 AS3MT:Arsenic (+3 oxidation state) methyltransferase ASMT:Acetylserotonin O-methyltransferase BAAT:Bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase) CBR1:Carbonyl reductase 1 CBR3:Carbonyl reductase 3 CBR4:Carbonyl reductase 4 CCBL1:Cysteine conjugate-beta lyase, cytoplasmic CDA:Cytidine deaminase CEL:Carboxyl ester lipase

Long-Form Names for Genes Listed in Table 27 .2

Alcohol dehydrogenase 1A (class I), alpha polypeptide AADAC:Arylacetamide deacetylase AANAT:Aralkylamine N-acetyltransferase ACSL1:Acyl-CoA synthetase long-chain family member 1 ACSL3:Acyl-CoA synthetase long-chain family member 3 ACSL4:Acyl-CoA synthetase long-chain family member 4 ACSM1:Acyl-CoA synthetase medium-chain family member 1 ACSM2B:Acyl-CoA synthetase medium-chain family member 2B ACSM3:Acyl-CoA synthetase medium-chain family, member 3 ADH1B:Alcohol dehydrogenase 1B (class I), beta polypeptide ADH1C:Alcohol dehydrogenase 1C (class I), gamma polypeptide ADH4:Alcohol dehydrogenase 4 (class II), pi polypeptide ADH5:Alcohol dehydrogenase 5 (class III), chi polypeptide ADH6:Alcohol dehydrogenase 6 (class V) ADH7:Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide ADHFE1:Alcohol dehydrogenase, iron containing, 1 AGXT:Alanine-glyoxylate aminotransferase AKR1A1:Aldo-keto reductase family 1, member A1 (aldehyde reductase) AKR1B1:Aldo-keto reductase family 1, member B1 (aldose reductase) AKR1C1:Aldo-keto reductase family 1, member C1 AKR1D1:Aldo-keto reductase family 1, member D1 ALDH1A1: Aldehyde dehydrogenase 1 family, member A1 Carboxylesterase 5A CHST1:Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 CHST2:Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 CHST3:Carbohydrate (chondroitin 6) sulfotransferase 3 CHST4:Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4 CHST5:Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 CHST6:Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 CHST7:Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 CHST8:Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 CHST9:Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 CHST10:Carbohydrate sulfotransferase 10 CHST11:Carbohydrate (chondroitin 4) sulfotransferase 11 CHST12:Carbohydrate (chondroitin 4) sulfotransferase 12 CHST13:Carbohydrate (chondroitin 4) sulfotransferase 13 COMT: Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit (non-catalytic) DHRS1:Dehydrogenase/reductase (SDR family) member 1 DHRS2:Dehydrogenase/reductase (SDR family) member 2 DHRS3:Dehydrogenase/reductase (SDR family) member 3 DHRS4:Dehydrogenase/reductase (SDR family) member 4 DHRS7:Dehydrogenase/reductase (SDR family) member 7

Dehydrogenase/reductase (SDR family) member 9 DHRS12:Dehydrogenase/reductase (SDR family) member 12 DHRS13:Dehydrogenase/reductase (SDR family) member 13 DHRSX:Dehydrogenase/reductase (SDR family) X-linked DPEP1:Dipeptidase 1 (renal) DPYD:Dihydropyrimidine dehydrogenase EPHX1:Epoxide hydrolase 1, microsomal (xenobiotic) EPHX2:Epoxide hydrolase 2, microsomal (xenobiotic) ESD:Esterase D FMO1:Flavin containing monooxygenase 1 FMO2:Flavin containing monooxygenase 2

Flavin containing monooxygenase 3 FMO4:Flavin containing monooxygenase 4 FMO5:Flavin containing monooxygenase 5 FMO6P:Flavin containing monooxygenase 6 pseudogene GAL3ST1:Galactose-3-O-sulfotransferase 1 GAMT:Guanidinoacetate N-methyltransferase GLRX:Glutaredoxin (thioltransferase) GLYAT:Glycine-N-acyltransferase GNMT:Glycine N-methyltransferase GPX1:Glutathione peroxidase 1 GPX2:Glutathione peroxidase 2 (gastrointestinal) GPX3:Glutathione peroxidase 3 (plasma) GPX4:Glutathione peroxidase 4 GPX5:Glutathione peroxidase 5 GPX6:Glutathione peroxidase 6 (olfactory) GPX7:Glutathione peroxidase 7 GSR:Glutathione reductase GSTA1:Glutathione S-transferase alpha 1 GSTA2:Glutathione S-transferase alpha 2 GSTA3:Glutathione S-transferase alpha 3 GSTA4:Glutathione S-transferase alpha 4 GSTA5:Glutathione S-transferase alpha 5 GSTCD:Glutathione S-transferase, C-terminal domain containing GSTK1:Glutathione S-transferase kappa 1 GSTM1:Glutathione S-transferase mu 1 GSTM2:Glutathione S-transferase mu 2 (muscle) GSTM3:Glutathione S-transferase mu 3 (brain) GSTM4:Glutathione S-transferase mu 4 GSTM5:Glutathione S-transferase mu 5 GSTO1:Glutathione S-transferase omega 1 GSTO2:Glutathione S-transferase omega 2 GSTP1:Glutathione S-transferase pi 1 GSTT1:Glutathione S-transferase theta 1 GSTT2:Glutathione S-transferase theta 2 GSTZ1:Glutathione S-transferase zeta 1 GZMA:Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)

Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)

Histamine N-methyltransferase HSD11B1:Hydroxysteroid (11-beta) dehydrogenase 1 HSD17B10: Hydroxysteroid (17-beta) dehydrogenase 10 HSD17B11: Hydroxysteroid (17-beta) dehydrogenase 11 HSD17B14: Hydroxysteroid (17-beta) dehydrogenase 14

Indolethylamine N-methyltransferase MAOA:Monoamine oxidase A MAOB: monoamine oxidase B

Methionyl aminopeptidase 1 MGST1:Microsomal glutathione S-transferase 1 MGST2:Microsomal glutathione S-transferase 1 MGST3:Microsomal glutathione S-transferase 3 NAA20:N(alpha)-acetyltransferase 20, NatB catalytic subunit NAT1: N-acetyltransferase 1 (arylamine N-acetyltransferase) NAT2:N-acetyltransferase 2 (arylamine N-acetyltransferase) NNMT:Nicotinamide N-methyltransferase NQO1: NAD(P)H dehydrogenase, quinone 1 NQO2: NAD(P)H dehydrogenase, quinone 2 PNMT:Phenylethanolamine N-methyltransferase PON1:Paraoxonase 1 PON2:Paraoxonase 2 PON3:Paraoxonase 3 POR:P450 (cytochrome) oxidoreductase PTGES:Prostaglandin E synthase PTGS1:Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) PTGS2:Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) SAT1:Spermidine/spermine N1-acetyltransferase 1 SMOX:Spermine oxidase SOD1:Superoxide dismutase 1, soluble SOD2:Superoxide dismutase 2, mitochondrial SULT1A1:Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 SULT1A2:Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 SULT1A3:Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 SULT1B1:Sulfotransferase family, cytosolic, 1B, member 1 SULT1C1:Sulfotransferase family, cytosolic, 1C, member 1 SULT1C2:Sulfotransferase family, cytosolic, 1C, member 2 SULT1C3:Sulfotransferase family, cytosolic, 1C, member 3 SULT1C4:Sulfotransferase family, cytosolic, 1C, member 4 SULT1E1:Sulfotransferase family 1E, estrogen-preferring, member 1 SULT2A1:Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 SULT2B1:Sulfotransferase family, cytosolic, 2B, member 1 SULT4A1:Sulfotransferase family 4A, member 1 SULT6B1:sulfotransferase family, cytosolic, 6B, member 1 TBXAS1:Thromboxane A synthase 1 (platelet) TPMT:Thiopurine S-methyltransferase TST:Thiopurine S-methyltransferase UCHL1:Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)

Ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) UGT1A1:UDP glucuronosyltransferase 1 family, polypeptide A1 UGT1A3:UDP glucuronosyltransferase 1 family, polypeptide A3 UGT1A4:UDP glucuronosyltransferase 1 family, polypeptide A4 UGT1A5:UDP glucuronosyltransferase 1 family, polypeptide A5 UGT1A6:UDP glucuronosyltransferase 1 family, polypeptide A6 UGT1A7:UDP glucuronosyltransferase 1 family, polypeptide A7 UGT1A8:UDP glucuronosyltransferase 1 family, polypeptide A8 UGT1A9:UDP glucuronosyltransferase 1 family, polypeptide A9 UGT1A10:UDP glucuronosyltransferase 1 family, polypeptide A10 UGT2A1:UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus UGT2A3:UDP glucuronosyltransferase 2 family, polypeptide A3 UGT2B10:UDP glucuronosyltransferase 2 family, polypeptide B10 UGT2B11:UDP glucuronosyltransferase 2 family, polypeptide B11 UGT2B15:UDP glucuronosyltransferase 2 family, polypeptide B15 UGT2B17:UDP glucuronosyltransferase 2 family, polypeptide B17 UGT2B28:UDP glucuronosyltransferase 2 family, polypeptide B28 UGT2B4:UDP glucuronosyltransferase 2 family, polypeptide B4 UGT2B7:UDP glucuronosyltransferase 2 family, polypeptide B7 UGT3A1:UDP glycosyltransferase 3 family, polypeptide A1 UGT8:UDP glycosyltransferase 8 XDH:Xanthine dehydrogenase